Choosing a peptide CDMO is one of the highest-leverage decisions a drug developer makes. The right partner accelerates your program and de-risks supply; the wrong one introduces delays, deviations, and rework at exactly the moments you can least afford them. This buyer's guide breaks down what a peptide CDMO does and how to evaluate one with confidence.
What does a peptide CDMO do?
A contract development and manufacturing organization develops, manufactures, tests, and supplies your peptide on your behalf. A full-service peptide CDMO spans process development, analytical development, GMP manufacturing, regulatory and CMC support, tech transfer, and validated commercial supply — ideally under a single quality system so your molecule does not change hands between phases.
CDMO vs CMO vs in-house
A CMO manufactures to a process you already own. A CDMO also helps you develop that process — valuable when your route is not yet locked. Building in-house gives maximum control but ties up capital and capacity that early-stage programs rarely have. For most peptide developers, a CDMO offers the best balance of expertise, flexibility, and speed.
A 12-point checklist for evaluating a peptide CDMO
- Range of scale — research through GMP commercial supply.
- Peptide chemistry depth (cyclic, stapled, non-natural amino acids, conjugation, long sequences).
- GMP and cGMP track record and inspection history.
- Data integrity (ALCOA+) and audit-ready documentation.
- Analytical capability and specification setting.
- Regulatory and CMC support for IND/IMPD and commercial filings.
- Tech transfer process and a dedicated technical lead.
- Capacity, redundancy, and supply continuity planning.
- Lead times and on-time delivery performance.
- Confidentiality and IP protection.
- Communication and project-management quality.
- References and case studies in comparable programs.
Quality systems and data integrity
Quality is non-negotiable. Look for GMP peptide manufacturing with ISO-aligned systems and data integrity built into every batch. Ask how records are controlled, how deviations and out-of-specification results are handled, and whether documentation is genuinely audit-ready rather than reconstructed after the fact. Our view on this is set out in our note on audit-ready data integrity.
Scale, capacity, and supply assurance
A CDMO that can make your first clinical batch but not your commercial demand is only half a partner. Confirm a clear path from custom peptide synthesis to commercial volumes, and probe capacity, redundancy, and continuity. As we argue in why supply assurance is a scientific decision, supply risk is ultimately scientific risk.
Regulatory and CMC support
If your peptide is an active ingredient, peptide API experience matters. The right CDMO supplies the characterization, stability data, and CMC documentation your submissions need, and understands how manufacturing choices ripple into regulatory filings.
Red flags to watch for
- Vague answers on quality systems, deviations, or data integrity.
- No clear scale-up path beyond clinical quantities.
- Reluctance to share documentation samples or references.
- One-method-fits-all chemistry regardless of your sequence.
Making the decision
Score candidates against the checklist, weight the criteria that matter most to your stage, and favor a partner who can grow with your molecule. Continuity — one partner, one quality system, from route to routine supply — is often worth more than a marginal price advantage. When you are ready, our team is happy to walk through your program.